Malecare Cancer Support's Advanced Prostate Cancer Program invites you to our teleconference on Provenge. The Teleconference will begin 6PM EDT, Monday, June 13, 2011. Please register at http://bit.ly/kKuByH Call in number and code will be emailed to you, along with info on how to ask your specific question of our guest. The teleconference will be [...]
Dr Aaron Katz and Dr. Philippa J. Cheetham from the Columbia University Medical Center in New York City are hosting a men’s health seminar on Father’s Day weekend, specifically on Saturday, June 18, 2011. Both Drs. Katz and Cheetham are board certified urological surgeons who specialize in the treatment of prostate cancer. You can also [...]
There are no right or wrong answers for men with prostate cancer when trying to decide what treatment to have, or even if they want to have treatment. One vital piece of information that is often left out of the equation is the chance of dying from prostate cancer if a man chooses not to [...]
Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]
Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]
Researchers from the Mayo Clinic recently announced results at the American Urological Association (AUA) Annual Meeting from a long-term study that indicates that surgery can improve life expectancy for men with advanced prostate cancer. Their study shows that 80% of men who have advanced prostate cancer and still choose to have surgery survive for at [...]
It is in the normal course of events that as our advanced prostate cancer progresses we will eventually end up dying from the disease. There will come a time when our doctors will no longer have any additional treatments or tricks up their sleeve, or we will just decide that we are done and wish [...]
On Sunday at the AUA conference there was a poster (#159) titled ADJUVANT VS. SALVAGE RADIATION THERAPY FOLLOWING PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM SEER-MEDICARE written by Keith J. Kowalczyk, etal. The researchers evaluated the optimal timing of external beam radiation (RT) after the completion of a radical prostatectomy (RP) as primary treatment [...]
For our European readers who have not yet started, but are getting ready to start hormone deprivation therapy (ADT), there is a new clinical trial you should consider. This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer. Enrolled men would not have had any previous hormonal therapies for [...]
Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
